Citations (103)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Roxana E Iacob, Stanley R Krystek, Richard Y-C Huang, Hui Wei, Li Tao, Zheng Lin, Paul E Morin, Michael L Doyle, Adrienne A Tymiak, John R Engen & Guodong Chen. (2015) Hydrogen/deuterium exchange mass spectrometry applied to IL-23 interaction characteristics: potential impact for therapeutics. Expert Review of Proteomics 12:2, pages 159-169.
Read now
Read now
Parthasarathy Seshacharyulu, Moorthy P Ponnusamy, Dhanya Haridas, Maneesh Jain, Apar K Ganti & Surinder K Batra. (2012) Targeting the EGFR signaling pathway in cancer therapy. Expert Opinion on Therapeutic Targets 16:1, pages 15-31.
Read now
Read now
Sonia Garofalo, Roberta Rosa, Roberto Bianco & Giampaolo Tortora. (2008) EGFR-targeting agents in oncology. Expert Opinion on Therapeutic Patents 18:8, pages 889-901.
Read now
Read now
Christian Ensinger & William Sterlacci. (2008) Implications of EGFR PharmDx™ Kit for cetuximab eligibility. Expert Review of Molecular Diagnostics 8:2, pages 141-148.
Read now
Read now
Susana M. Campos. (2008) Anti-Epidermal Growth Factor Receptor Strategies for Advanced Breast Cancer. Cancer Investigation 26:8, pages 757-768.
Read now
Read now
D. Mckillop, A. D. Mccormick, G. S. Miles, P. J. Phillips, K. J. Pickup, N. Bushby & M. Hutchison. (2004) In vitro metabolism of gefitinib in human liver microsomes. Xenobiotica 34:11-12, pages 983-1000.
Read now
Read now
Herbert B Newton. (2003) Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: growth factor and Ras signaling pathways. Expert Review of Anticancer Therapy 3:5, pages 595-614.
Read now
Read now
Mazen Y Khalil, Jennifer R Grandis & Dong M Shin. (2003) Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer. Expert Review of Anticancer Therapy 3:3, pages 367-380.
Read now
Read now
Articles from other publishers (95)
Rei Noguchi, Akihiro Yoshimura, Junji Uchino, Takayuki Takeda, Yusuke Chihara, Takayo Ota, Osamu Hiranuma, Hiroshi Gyotoku, Koichi Takayama & Tadashi Kondo. (2023) Comprehensive Kinase Activity Profiling Revealed the Kinase Activity Patterns Associated with the Effects of EGFR Tyrosine Kinase Inhibitor Therapy in Advanced Non-Small-Cell Lung Cancer Patients with Sensitizing EGFR Mutations. Proteomes 11:1, pages 6.
Crossref
Crossref
Sitanshu Mondal, Vishakha S., Kumari Das Kajal, Simranpreet K. Wahan, Balak Das Kurmi & Preeti Patel. (2023) Current Trends in the Development of EGFR Inhibitors as Promising Anticancer
Agents: Sar and Synthetic Studies from (2010-2020). Current Organic Chemistry 27:1, pages 2-27.
Crossref
Crossref
Ekaterina V. Orlova. (2021) Physiological functions of keratinocyte epidermal growth factor receptors and their role in the development of skin toxicity during targeted cancer therapy. Russian Journal of Skin and Venereal Diseases 24:2, pages 111-118.
Crossref
Crossref
Pushpamali De Silva, Mohammad A. Saad, Hanna C. Thomsen, Shazia Bano, Shoaib Ashraf & Tayyaba Hasan. (2020) Photodynamic therapy, priming and optical imaging: Potential co-conspirators in treatment design and optimization — a Thomas Dougherty Award for Excellence in PDT paper. Journal of Porphyrins and Phthalocyanines 24:11n12, pages 1320-1360.
Crossref
Crossref
Yutang Huang, Yi Dai, Chunjie Wen, Shuai He, Jingjing Shi, Dezhang Zhao, Lanxiang Wu & Honghao Zhou. (2020) circSETD3 Contributes to Acquired Resistance to Gefitinib in Non-Small-Cell Lung Cancer by Targeting the miR-520h/ABCG2 Pathway. Molecular Therapy - Nucleic Acids 21, pages 885-899.
Crossref
Crossref
Pradhan Saheli, Mitra Shouvik & Goswami Arunava. (2020) Anticancer activity of novel surface functionalized metal doped hydroxyapatite. Archives of Pharmacy and Pharmaceutical Sciences 4:1, pages 021-026.
Crossref
Crossref
Ayah Abdeldayem, Yasir S. Raouf, Stefan N. Constantinescu, Richard Moriggl & Patrick T. Gunning. (2020) Advances in covalent kinase inhibitors. Chemical Society Reviews 49:9, pages 2617-2687.
Crossref
Crossref
Deepak KGK, Seema Kumari, Shailender G & Rama Rao Malla. (2020) Marine natural compound cyclo(L-leucyl-L-prolyl) peptide inhibits migration of triple negative breast cancer cells by disrupting interaction of CD151 and EGFR signaling. Chemico-Biological Interactions 315, pages 108872.
Crossref
Crossref
Jiuyang He, Chenchen Li, Lin Ding, Yanan Huang, Xuelian Yin, Junfeng Zhang, Jian Zhang, Chenjie Yao, Minmin Liang, Rogério P. Pirraco, Jie Chen, Quan Lu, Ryan Baldridge, Yong Zhang, Minghong Wu, Rui L. Reis & Yanli Wang. (2019) Tumor Targeting Strategies of Smart Fluorescent Nanoparticles and Their Applications in Cancer Diagnosis and Treatment. Advanced Materials 31:40, pages 1902409.
Crossref
Crossref
Pragya Misra & Shailza Singh. (2019) Role of cytokines in combinatorial immunotherapeutics of non‐small cell lung cancer through systems perspective. Cancer Medicine 8:5, pages 1976-1995.
Crossref
Crossref
Hongbo Zhao, Yutang Huang, Jingjing Shi, Yi Dai, Lanxiang Wu & Honghao Zhou. (2018) ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC. Frontiers in Pharmacology 9.
Crossref
Crossref
Puja Sharma & Waldemar Debinski. (2018) Receptor-Targeted Glial Brain Tumor Therapies. International Journal of Molecular Sciences 19:11, pages 3326.
Crossref
Crossref
Zhichen Sun, Yang-Xin Fu & Hua Peng. (2018) Targeting tumor cells with antibodies enhances anti-tumor immunity. Biophysics Reports 4:5, pages 243-253.
Crossref
Crossref
Xue Yang, Qian Xiong, Ying Wu, Siting Li & Feng Ge. (2017) Quantitative Proteomics Reveals the Regulatory Networks of Circular RNA CDR1as in Hepatocellular Carcinoma Cells. Journal of Proteome Research 16:10, pages 3891-3902.
Crossref
Crossref
Zhuo Chen, Suresh Ramalingam & Dong M. Shin. 2017. The Molecular Basis of Human Cancer. The Molecular Basis of Human Cancer
709
726
.
Ibrahim O Alanazi & Zahid Khan. (2016) Understanding EGFR Signaling in Breast Cancer and Breast Cancer Stem Cells: Overexpression and Therapeutic Implications. Asian Pacific Journal of Cancer Prevention 17:2, pages 445-453.
Crossref
Crossref
Roxana E. Iacob, Guodong Chen, Joomi Ahn, Stephane Houel, Hui Wei, Jingjie Mo, Li Tao, Daniel Cohen, Dianlin Xie, Zheng Lin, Paul E. Morin, Michael L. Doyle, Adrienne A. Tymiak & John R. Engen. (2014) The Influence of Adnectin Binding on the Extracellular Domain of Epidermal Growth Factor Receptor. Journal of the American Society for Mass Spectrometry 25:12, pages 2093-2102.
Crossref
Crossref
MIN WU, YUAN YUAN, YUE-YIN PAN & YING ZHANG. (2014) Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Molecular Medicine Reports 10:2, pages 931-938.
Crossref
Crossref
Shuang-xi Li, Li-juan Liu, Li-wei Dong, Hong-guang Shi, Yu-fei Pan, Ye-xiong Tan, Jian Zhang, Bo Zhang, Zhi-wen Ding, Tian-yi Jiang, He-ping Hu & Hong-yang Wang. (2014) CKAP4 inhibited growth and metastasis of hepatocellular carcinoma through regulating EGFR signaling. Tumor Biology 35:8, pages 7999-8005.
Crossref
Crossref
Sahil Aggarwal, Swati Gupta, Dilrose Pabla & R. S. R. Murthy. (2013) Gemcitabine-loaded PLGA-PEG immunonanoparticles for targeted chemotherapy of pancreatic cancer. Cancer Nanotechnology 4:6, pages 145-157.
Crossref
Crossref
Viswanath Reddy Belum, Andrea Cercek, Virginia Sanz-Motilva & Mario E. Lacouture. (2013) Dermatologic Adverse Events to Targeted Therapies in Lower GI Cancers: Clinical Presentation and Management. Current Treatment Options in Oncology 14:3, pages 389-404.
Crossref
Crossref
Yeon-Sik Choi, Gyoo-Cheon Kim, Sik Yoon, Dae-Seok Hwang, Cheol-Hun Kim, Young-Chan Jeon, June-Ho Byun, Sang-Hun Shin & Uk-Kyu Kim. (2013)
Induction of Selective Cell Death of Oral Squamous Carcinoma Cells by Integrin α
2
Antibody and EGFR Antibody
. The Journal Of Korean Association of Maxillofacial Plastic and Reconstructive Surgeons 35:3, pages 143-154.
Crossref
Crossref
Kristian Sexton, Kenneth Tichauer, Kimberley S. Samkoe, Jason Gunn, P. Jack Hoopes & Brian W. Pogue. (2013) Fluorescent Affibody Peptide Penetration in Glioma Margin Is Superior to Full Antibody. PLoS ONE 8:4, pages e60390.
Crossref
Crossref
Batzaya Byambaa, Tomohiro Konno & Kazuhiko Ishihara. (2013) Detachment of cells adhered on the photoreactive phospholipid polymer surface by photoirradiation and their functionality. Colloids and Surfaces B: Biointerfaces 103, pages 489-495.
Crossref
Crossref
Jasmine G. Lee & Reen Wu. (2012) Combination Erlotinib-Cisplatin and Atg3-Mediated Autophagy in Erlotinib Resistant Lung Cancer. PLoS ONE 7:10, pages e48532.
Crossref
Crossref
Adriana Romiti, Chiara D’Antonio, Angelo Zullo, Ida Sarcina, Roberta Di Rocco, Viola Barucca, Valeria Durante & Paolo Marchetti. (2012) Chemotherapy for the Biliary Tract Cancers: Moving Toward Improved Survival Time. Journal of Gastrointestinal Cancer 43:3, pages 396-404.
Crossref
Crossref
Shaad E. Abdullah, Missak Haigentz & Bilal Piperdi. (2012) Dermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR: Pathophysiology and Management. Chemotherapy Research and Practice 2012, pages 1-10.
Crossref
Crossref
Dongsheng Wang, Ling Su, Donghai Huang, Hongzheng Zhang, Dong M Shin & Zhuo G Chen. (2011) Downregulation of E-Cadherin enhances proliferation of head and neck cancer through transcriptional regulation of EGFR. Molecular Cancer 10:1.
Crossref
Crossref
Alexander Konson, Sunila Pradeep, Cosimo Walter D'Acunto & Rony Seger. (2011) Pigment Epithelium-derived Factor and Its Phosphomimetic Mutant Induce JNK-dependent Apoptosis and p38-mediated Migration Arrest. Journal of Biological Chemistry 286:5, pages 3540-3551.
Crossref
Crossref
A Gabriella Wernicke, Adam P Dicker, Michal Whiton, Jana Ivanidze, Terry Hyslop, Elizabeth H Hammond, Arie Perry, David W Andrews & Lawrence Kenyon. (2010) Assessment of Epidermal Growth Factor Receptor (EGFR) expression in human meningioma. Radiation Oncology 5:1.
Crossref
Crossref
Siu-Fun Wong, Alexander Lindgren, Madhavi Mummaneni, Timothy Byun, Catherine Vasko, Rachel Arenos, Edward Alexson & Kathryn Osann. (2010) A Prospective Crossover Pilot Study to Evaluate the Use of a Topical Wound Gel in Patients with Cutaneous Toxicity Caused by Epidermal Growth Factor Receptor Inhibitors. The Journal of Supportive Oncology 8:5, pages 202-208.
Crossref
Crossref
Susana M. Campos, Suzanne T. Berlin, Leroy M. Parker, Wendy Y. Chen, Craig A. Bunnell, Tina Atkinson, Julie Lee, Ursula Matulonis, Michelle S. Hirsch, Lyndsay Harris & Carolyn N. Krasner. (2010) Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer. International Journal of Clinical Oncology 15:4, pages 390-398.
Crossref
Crossref
Qi-Feng JIANG, Shao-Xi CAI & Xiao-Qing YAN. (2010) The Effect of Caldesmon Phosphorylation on Metastatic Tumor Cell Mobility*. PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS 37:3, pages 326-336.
Crossref
Crossref
Chitta Ranjan Patra, Resham Bhattacharya, Debabrata Mukhopadhyay & Priyabrata Mukherjee. (2010) Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer. Advanced Drug Delivery Reviews 62:3, pages 346-361.
Crossref
Crossref
C.-L. Albert Wang & Lynne M. Coluccio. 2010.
91
128
.
Roberto Bianco, Teresa Gelardi, Sonia Garofalo, Roberta Rosa & Giampaolo Tortora. 2010. Macromolecular Anticancer Therapeutics. Macromolecular Anticancer Therapeutics
407
436
.
Muhammad Wasif Saif, J. Peccerillo & Von Potter. (2008) Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature. Cancer Chemotherapy and Pharmacology 63:6, pages 1017-1022.
Crossref
Crossref
Valentin Giroux, Jean-Charles Dagorn & Juan L. Iovanna. (2009) A Review of Kinases Implicated in Pancreatic Cancer. Pancreatology 9:6, pages 738-754.
Crossref
Crossref
Carmen Giefing, Eszter Nagy & Alexander von Gabain. 2009. Pharmaceutical Biotechnology. Pharmaceutical Biotechnology
90
117
.
Maria S. Pino, Michele Balsamo, Francesca Di Modugno, Marcella Mottolese, Massimo Alessio, Elisa Melucci, Michele Milella, David J. McConkey, Ulrike Philippar, Frank B. Gertler, Pier Giorgio Natali & Paola Nisticò. (2008) Human Mena+11a Isoform Serves as a Marker of Epithelial Phenotype and Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Pancreatic Cancer Cell Lines. Clinical Cancer Research 14:15, pages 4943-4950.
Crossref
Crossref
Susan Muller, Ling Su, Mourad Tighiouart, Nabil Saba, Hongzheng Zhang, Dong M. Shin & Zhuo (Georgia) Chen. (2008) Distinctive E‐cadherin and epidermal growth factor receptor expression in metastatic and nonmetastatic head and neck squamous cell carcinoma. Cancer 113:1, pages 97-107.
Crossref
Crossref
Susan Goodin. (2008) Development of monoclonal antibodies for the treatment of colorectal cancer. American Journal of Health-System Pharmacy 65:11_Supplement_4, pages S3-S7.
Crossref
Crossref
Zhong J. Zhang & Maher Albitar. 2008. Molecular Biomethods Handbook. Molecular Biomethods Handbook
547
561
.
Mark L. Sundermeyer, Alfonso Bellacosa & Neal J. Meropol. 2008. Molecular Targeting in Oncology. Molecular Targeting in Oncology
133
163
.
Russell P. Kruzelock & William Short. (2007) Colorectal Cancer Therapeutics and the Challenges of Applied Pharmacogenomics. Current Problems in Cancer 31:5, pages 315-366.
Crossref
Crossref
Roberto Bianco, Teresa Gelardi, Vincenzo Damiano, Fortunato Ciardiello & Giampaolo Tortora. (2007) Rational bases for the development of EGFR inhibitors for cancer treatment. The International Journal of Biochemistry & Cell Biology 39:7-8, pages 1416-1431.
Crossref
Crossref
Susana M. Campos. 2007. Breast Cancer: Translational Therapeutic Strategies. Breast Cancer: Translational Therapeutic Strategies
213
234
.
Michael Cohenuram & Muhammad Wasif Saif. (2007) Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anti-Cancer Drugs 18:1, pages 7-15.
Crossref
Crossref
Mebea Aklilu & David H. Ilson. (2007) Targeted Agents and Esophageal Cancer—The Next Step?. Seminars in Radiation Oncology 17:1, pages 62-69.
Crossref
Crossref
Shantaram Kamath & John K. Buolamwini. (2006) Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development. Medicinal Research Reviews 26:5, pages 569-594.
Crossref
Crossref
Sinto Sebastian, Jeffrey Settleman, Stephan J. Reshkin, Amalia Azzariti, Antonia Bellizzi & Angelo Paradiso. (2006) The complexity of targeting EGFR signalling in cancer: From expression to turnover. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1766:1, pages 120-139.
Crossref
Crossref
Ilaria Bellezza, Sergio Bracarda, Claudia Caserta & Alba Minelli. (2006) Targeting of EGFR tyrosine kinase by ZD1839 (?Iressa?) in androgen-responsive prostate cancer in vitro. Molecular Genetics and Metabolism 88:2, pages 114-122.
Crossref
Crossref
Maria S. Pino, Marissa Shrader, Cheryl H. Baker, Francesco Cognetti, Henry Q. Xiong, James L. Abbruzzese & David J. McConkey. (2006) Transforming Growth Factor α Expression Drives Constitutive Epidermal Growth Factor Receptor Pathway Activation and Sensitivity to Gefitinib (Iressa) in Human Pancreatic Cancer Cell Lines. Cancer Research 66:7, pages 3802-3812.
Crossref
Crossref
A. Lostumbo, D. Mehta, S. Setty & R. Nunez. (2006) Flow cytometry: A new approach for the molecular profiling of breast cancer. Experimental and Molecular Pathology 80:1, pages 46-53.
Crossref
Crossref
Debra Wujcik. (2006) EGFR as a Target: Rationale for Therapy. Seminars in Oncology Nursing 22, pages 5-9.
Crossref
Crossref
Siu-Fun Wong. (2005) Cetuximab: An epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. Clinical Therapeutics 27:6, pages 684-694.
Crossref
Crossref
Liana Adam, Wassim Kassouf & Colin P.N. Dinney. (2005) Clinical Applications for Targeted Therapy in Bladder Cancer. Urologic Clinics of North America 32:2, pages 239-246.
Crossref
Crossref
Edward S. Kim. (2004) Cetuximab as a Single Agent or in Combination with Chemotherapy in Lung Cancer. Clinical Lung Cancer 6, pages S80-S84.
Crossref
Crossref
Eva M. Schmelz, Edi Levi, Jianhua Du, Hu Xu & Adhip P.N. Majumdar. (2004) Age-related loss of EGF-receptor related protein (ERRP) in the aging colon is a potential risk factor for colon cancer. Mechanisms of Ageing and Development 125:12, pages 917-922.
Crossref
Crossref
Tadahiko Shien, Hiroyoshi Doihara, Humikata Hara, Hirotoshi Takahashi, Seiji Yoshitomi, Naruto Taira, Youiti Ishibe, Jyun Teramoto, Motoi Aoe & Nobuyoshi Shimizu. (2004) PLC and PI3K Pathways are Important in the Inhibition of EGF-lnduced Cell Migration by Gefitinib (‘lressa’, ZD1839). Breast Cancer 11:4, pages 367-373.
Crossref
Crossref
Roy S Herbst. (2004) Review of epidermal growth factor receptor biology. International Journal of Radiation Oncology*Biology*Physics 59:2, pages S21-S26.
Crossref
Crossref
Alessandro Dondoni, Alessandro Massi, Erik Minghini & Valerio Bertolasi. (2004) Multicomponent Hantzsch cyclocondensation as a route to highly functionalized 2- and 4-dihydropyridylalanines, 2- and 4-pyridylalanines, and their N-oxides: preparation via a polymer-assisted solution-phase approach. Tetrahedron 60:10, pages 2311-2326.
Crossref
Crossref
Dong Cho Han, Mi-Young Lee, Ki Deok Shin, Sun Bok Jeon, Jung Min Kim, Kwang-Hee Son, Hyoung-Chin Kim, Hwan-Mook Kim & Byoung-Mog Kwon. (2004) 2′-Benzoyloxycinnamaldehyde Induces Apoptosis in Human Carcinoma via Reactive Oxygen Species. Journal of Biological Chemistry 279:8, pages 6911-6920.
Crossref
Crossref
Jern-Lin Leong, Kwok Seng Loh, Thomas Choudhary Putti, Boon Cher Goh & Luke Kim Siang Tan. (2004) Epidermal Growth Factor Receptor in Undifferentiated Carcinoma of the Nasopharynx. The Laryngoscope 114:1, pages 153-157.
Crossref
Crossref
Roy S. Herbst, Amir Onn & John Mendelsohn. 2004. Signal Transduction in Cancer. Signal Transduction in Cancer
19
72
.
Nancy L. Lewis & Neal J. Meropol. (2003) Development of New Agents for the Treatment of Advanced Colorectal Cancer. Clinical Colorectal Cancer 3:3, pages 154-164.
Crossref
Crossref
Donald J Buchsbaum, James A Bonner, William E Grizzle, Murray A Stackhouse, Mark Carpenter, Daniel J Hicklin, Peter Bohlen & Kevin P Raisch. (2002) Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. International Journal of Radiation Oncology*Biology*Physics 54:4, pages 1180-1193.
Crossref
Crossref
F. Wang, R. K. Hansen, D. Radisky, T. Yoneda, M. H. Barcellos-Hoff, O. W. Petersen, E. A. Turley & M. J. Bissell. (2002) Phenotypic Reversion or Death of Cancer Cells by Altering Signaling Pathways in Three-Dimensional Contexts. JNCI Journal of the National Cancer Institute 94:19, pages 1494-1503.
Crossref
Crossref
Julia Gee & Robert Nicholson. 2002. Breast Cancer. Breast Cancer
301
342
.
Julia Gee. 2002. Endocrine Management of Breast Cancer. Endocrine Management of Breast Cancer
265
274
.
Patricia A. Spencer-Cisek. (2002) The role of growth factors in maligancy: A focus on the epidermal growth factor receptor. Seminars in Oncology Nursing 18, pages 13-19.
Crossref
Crossref
Elizabeth S. Waxman & Roy S. Herbst. (2002) The role of the epidermal growth factor receptor in the treatment of colorectal carcinoma. Seminars in Oncology Nursing 18, pages 20-29.
Crossref
Crossref
Roy S. Herbst & Dong M. Shin. (2002) Monoclonal antibodies to target epidermal growth factor receptor–positive tumors. Cancer 94:5, pages 1593-1611.
Crossref
Crossref
Rebecca S. Finley. (2016) New Directions in the Treatment of Cancer: Inhibition of Signal Transduction. Journal of Pharmacy Practice 15:1, pages 5-16.
Crossref
Crossref
Roy S Herbst & Corey J Langer. (2002) Epidermal growth factor receptors as a target for cancer treatment: The emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Seminars in Oncology 29:1, pages 27-36.
Crossref
Crossref
Eric K. Rowinsky. 2002. Colorectal Cancer. Colorectal Cancer
759
793
.
Paul A. BunnJr.Jr. & Karen Kelly. (2000) Combinations of Three Chemotherapeutic Agents and Two Chemotherapeutic Agents Plus a Targeted Biologic Agent in the Treatment of Advanced Non?Small-Cell Lung Cancer. Clinical Lung Cancer 2, pages S23-S28.
Crossref
Crossref
Michael R. Hamblin, Jaimie L. Miller & Bernhard Ortel. (2007) Scavenger-Receptor Targeted Photodynamic Therapy¶. Photochemistry and Photobiology 72:4, pages 533-540.
Crossref
Crossref
Michael R. Hamblin, Jaimie L. Miller & Bernhard Ortel. (2000) Scavenger-Receptor Targeted Photodynamic Therapy¶. Photochemistry and Photobiology 72:4, pages 533.
Crossref
Crossref
Y. Z. Hui, A. E. Noffsinger, M. A. Miller, P. Hurtubise & C. M. Fenoglio-Preiser. (1999) Strong Epidermal Growth Factor Receptor Expression But Not HER2/neu Expression Correlates with Cell Proliferation in Anal Canal Carcinomas. International Journal of Surgical Pathology 7:4, pages 193-203.
Crossref
Crossref
J.R Woodburn. (1999) The Epidermal Growth Factor Receptor and Its Inhibition in Cancer Therapy. Pharmacology & Therapeutics 82:2-3, pages 241-250.
Crossref
Crossref
Jong Myung Yoon, Seung Hee Han, Oh Byung Kown, Seung Ho Kim, Myung Hwan Park & Byong Kak Kim. (1999) Cloning and cytotoxicity of fusion proteins of EGF and angiogenin. Life Sciences 64:16, pages 1435-1445.
Crossref
Crossref
R. SENEKOWITSCH-SCHMIDTKE. (1999) Binding of EGF Peptide and EGF Receptor Antibodies and Its Fragments in Different Tumor Models. Hybridoma 18:1, pages 29-35.
Crossref
Crossref
Teruaki Kobayashi, Koji Hashimoto, Hidenobu Okumura, Hideo Asada & Kunihiko Yoshikawa. (1998) Endogenous EGF-Family Growth Factors are Necessary for the Progression from the G1 to S Phase in Human Keratinocytes. Journal of Investigative Dermatology 111:4, pages 616-620.
Crossref
Crossref
Emiko Tsuchida, Masanori Tsuchida & Muneyasu Urano. (1997) Synergistic Cytotoxicity between a Protein Kinase C Inhibitor, UCN-01, and Monoclonal Antibody to the Epidermal Growth Factor Receptor on MDA-468 Cells. Cancer Biotherapy and Radiopharmaceuticals 12:2, pages 117-121.
Crossref
Crossref
R. I. Nicholson, J. M. W. Gee, H. Jones, M. E. Harper, A. E. Wakeling, P. Willsher & J. F. R. Robertson. 1997. EGF Receptor in Tumor Growth and Progression. EGF Receptor in Tumor Growth and Progression
105
128
.
A. E. Wakeling, A. J. Barker, D. H. Davies, D. S. Brown, L. R. Green, S. A. Cartlidge & J. R. Woodburn. (1996) Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines. Breast Cancer Research and Treatment 38:1, pages 67-73.
Crossref
Crossref
Jeffrey W. Clark, Anabela Santos-Moore, Lisa E. Stevenson & A. Raymond Frackelton. (1996) Effects of tyrosine kinase inhibitors on the proliferation of human breast cancer cell lines and proteins important in the RAS signaling pathway. International Journal of Cancer 65:2, pages 186-191.
Crossref
Crossref
David S. Salomon, Ralf Brandt, Fortunato Ciardiello & Nicola Normanno. (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Critical Reviews in Oncology/Hematology 19:3, pages 183-232.
Crossref
Crossref
David S. Salomon, Nicola Normanno, Fortunato Ciardiello, Ralf Brandt, Mohammed Shoyab & George J. Todaro. (1995) The role of amphiregulin in breast cancer. Breast Cancer Research and Treatment 33:2, pages 103-114.
Crossref
Crossref
Steven P. Leon, Jiguang Zhu & Peter McL. Black. (1994) Genetic Aberrations in Human Brain Tumors. Neurosurgery 34:4, pages 708-722.
Crossref
Crossref
Garth Powis. (1994) Signalling pathways as target for anticancer drug development. Pharmacology & Therapeutics 62:1-2, pages 57-95.
Crossref
Crossref
Mark A. Israel. 1993.
57
85
.
H. Modjtahedi, S. A. Eccles, G. Box, J. Styles & C. J. Dean. (1993) Antitumor activity of combinations of antibodies directed against different epitopes on the extracellular domain of the human EGF receptor. Cell Biophysics 22:1-3, pages 129-146.
Crossref
Crossref
Pragya Misra & Shailza Singh. (2018) Role of Cytokines in Combinatorial Immunotherapeutics of Non-Small Cell Lung Cancer Through Systems Perspective. SSRN Electronic Journal.
Crossref
Crossref